From Wikipedia, the free encyclopedia
Chemical compound
Mirogabalin
|
|
Trade names | Tarlige |
---|
Other names | DS-5565 |
---|
Routes of administration |
By mouth |
---|
ATC code | |
---|
|
(1R,5S,6S)-6-(aminomethyl)-3-ethyl-bicyclo(3.2.0)hept-3-ene-6-acetic acid
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
|
Formula | C12H19NO2 |
---|
Molar mass | 209.289 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CCC1=CC2C(C1)C[C@@]2(CN)CC(=O)O
|
InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1 Key:FTBQORVNHOIASH-CKYFFXLPSA-N
|
Mirogabalin (brand name Tarlige; developmental code name DS-5565) is a
gabapentinoid medication developed by
Daiichi Sankyo.
Gabapentin and
pregabalin are also members of this class. As a gabapentinoid, mirogabalin binds to the
α2δ subunit of voltage-gated calcium channel (
1 and
2), but with significantly higher potency than pregabalin. It has shown promising results in Phase II
clinical trials for the treatment of
diabetic peripheral neuropathic pain.
[1]
[2]
Phase III trial results:
In Japan, the company submitted a marketing application for treatment of
peripheral neuropathic pain.
[5] The medication was approved for
neuropathic pain and
postherpetic neuralgia in Japan in January 2019.
[6]
References
-
^ Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D (December 2014).
"Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study". Diabetes Care. 37 (12): 3253–61.
doi:
10.2337/dc14-1044.
PMID
25231896.
-
^ Vinik A, Sharma U, Feins K, Hsu C, Merante D (2014).
"DS-5565 for the Treatment Of Diabetic Peripheral Neuropathic Pain: Randomized, Double-Blind, Placebo- And Active Comparator-Controlled Phase II Study (S20.004)". Neurology. 82 (10): S20.004.
-
^
"Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes". Daiichi Sankyo. 30 June 2017.
-
^
"Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain". Daiichi Sankyo. 31 August 2017.
-
^
"Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan". Daiichi Sankyo. 15 February 2018.
-
^
"Mirogabalin - Daiichi Sankyo Company - AdisInsight".
External links
-
"Mirogabalin". Drug Information Portal. U.S. National Library of Medicine.
|
---|
Calcium |
VDCCsTooltip Voltage-dependent calcium channels | |
---|
|
---|
Potassium |
VGKCsTooltip Voltage-gated potassium channels | |
---|
IRKsTooltip Inwardly rectifying potassium channel | |
---|
KCaTooltip Calcium-activated potassium channel | |
---|
K2PsTooltip Tandem pore domain potassium channel | |
---|
|
---|
Sodium |
VGSCsTooltip Voltage-gated sodium channels | |
---|
ENaCTooltip Epithelial sodium channel | |
---|
ASICsTooltip Acid-sensing ion channel | |
---|
|
---|
Chloride |
CaCCsTooltip Calcium-activated chloride channel | |
---|
CFTRTooltip Cystic fibrosis transmembrane conductance regulator | |
---|
Unsorted | |
---|
|
---|
Others |
TRPsTooltip Transient receptor potential channels | |
---|
LGICsTooltip Ligand gated ion channels | |
---|
|
---|
|